論文（英文）

• Nagata N, Mishima H, Kurosawa S, Oba K, Sakamoto J. mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale. Clin Colorectal Cancer 2017; 16(2):154-157.e1.
• Shiga M, Maeda H, Oba K, Okamoto K, Namikawa T, Fujisawa K, Yokota K, Kobayashi M, Hanazaki K. Safety of laparoscopic surgery for colorectal cancer in patients over 80 years old: a propensity score matching study. Surg Today. 2017 Jan 27. [Epub ahead of print]
• Shinozaki T, Mansournia MA, Matsuyama Y. On hazard ratio estimators by proportional hazards models in matched-pair cohort studies. Emerg Themes Epidemiol. 2017;14:6.
• Otsuka T, Mizuno K, Shinozaki T, Kachi Y, Nakamura H. Preventive effect of pravastatin on the development of hypertension in patients with hypercholesterolemia: a post-hoc analysis of the MEGA Study. J Clin Lipidol. 2017;11(4):998-1006.
• Takeuchi Y, Ando T, Ishiguro C, Uyama Y. Risk of acute asthma attacks associated with non-steroidal anti-inflammatory drugs: A self-controlled case series. Ther Innov Regul Sci. 2017; 51(3): 332–341.
• Kuramitsu S, Jinnouchi H, Shinozaki T, Matsuda H, Hiromasa T, Matsumura Y, Yamaji Y, Miura M, Masuda H, Domei T, Soga Y, Hyodo M, Shirai S, Ando K. Incidence and long-term clinical impact of late-acquired stent fracture after sirolimus-eluting stent implantation in narrowed coronary arteries. Am J Cardiol. 2017;120(1):55-62.
• Nishizaki Y, Mizuno A, Shinozaki T, Okubo T, Tsugawa Y, Shimizu T, Konishi R, Yamamoto Y, Yanagisawa N, Shiojiri T, Tokuda Y. Educational environment and the improvement in the General Medicine In-training Examination score (Letter). J Gen Fam Med. 2017;18(5):312-4.
• Shinozaki T, Hagiwara Y, Matsuyama Y. Re. Biases in randomized trials: a conversation between trialists and epidemiologists (Letter). Epidemiology. 2017; 28(4): e40-e41.
• Hagiwara Y, Ohashi Y, Okusaka T, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Cheng AL, Kihara K, Sato A, Tanaka M. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. ESMO Open. 2017;2:e000151.
• Yamaue H, Shimizu A, Hagiwara Y, Sho M, Yanagimoto H, Nakamori S, Ueno H, Ishii H, Kitano M, Sugimori K, Maguchi H, Ohkawa S, Imaoka H, Hashimoto D, Ueda K, Nebiki H, Nagakawa T, Isayama H, Yokota I, Ohashi Y, Shirasaka T. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer. Cancer Chemother Pharmacol. 2017;79:813-823.
• Ikeda T, Uchida K, Yamauchi Y, Nagase T, Oba K, Yamada Y. Relationship between pre-anesthetic and intra-anesthetic airway resistance in patients undergoing general anesthesia: A prospective observational study. PLoS One 2017;12(2):e0172421.
• Nakamura M, Aoyama T, Ishibashi K, Tsuji A, Takinishi Y, Shindo Y, Sakamoto J, Oba K, Mishima H. Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study). Cancer Chemother Pharmacol 2017;79:29-36.
• Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemother Pharmacol 2016;78:1253-1261.
• Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). PLoS One. 2016 Oct 6;11:e0164255.
• Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer. Ann Surg Oncol. 2016 Sep 8.
• Toyoda H, Tada T, Johnson PJ, Izumi N, Kadoya M, Kaneko S, Kokudo N, Ku Y, Kubo S, Kumada T, Matsuyama Y, Nakashima O, Sakamoto M, Takayama T, Kudo M; Liver Cancer Study Group of Japan. Validation of serological models for staging and prognostication of HCC in patients from a Japanese nationwide survey. J Gastroenterol. 2017;52(10):1112-21.
• Saitoh A, Saitoh A, Sato I, Shinozaki T, Kamiya H, Nagata S. Effect of stepwise perinatal immunization education: a cluster-randomized controlled trial. Vaccine. 2017;35(12):1645-51.
• Jinnouchi H, Kuramitsu S, Shinozaki T, Tomoi Y, Hiromasa T, Kobayashi Y, Domei T, Soga Y, Hyodo M, Shirai S, Ando K. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation: an optical coherence tomography study. Circ J. 2017;81(4):450-7.
• Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y. Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA). Int J Cardiovasc Imaging. 2017;33(6):779-787. doi: 10.1007/s10554-017-1068-4.
• Taniguchi Y, Kitamura A, Murayama H, Amano H, Shinozaki T, Yokota I, Seino S, Nofuji Y, Nishi M, Yokoyama Y, Matsuyama Y, Fujuwara Y, Shinkai S. Mini-Mental State Examination Score Trajectories and Incident Disabling Dementia Among Community-Dwelling Older Japanese. Geriatr Gerontol Int. 2017;17(11):1928-35.

TOP